Literature DB >> 11680568

Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation?

J G Gaca1, W Lee, O Aksoy, S J Braedehoeft, G V Gonzalez-Stawinski, W Parker, R D Davis.   

Abstract

The xenoreactive nature of anti-Galalpha1-3Gal antibodies, and to a lesser extent, polyreactive antibodies, has been characterized by a number of investigators. With the advent of therapies that avoid hyperacute xenograft rejection due to anti-Galalpha1-3Gal antibodies coupled with the possible development of Galalpha1-3Gal deficient swine, the Galalpha1-3Gal antigen may soon cease to be a barrier to xenotransplantation. With this in mind, the potential xenoreactive nature of polyreactive antibodies was investigated using several approaches. The levels of polyreactive antibodies from the serum of newborn (n = 2) and adult (n = 4) baboons undergoing pulmonary xenotransplantation were evaluated. Depletion of 95% and 94% of total serum IgM, without any decrease in albumin levels, was observed in the newborn baboons. This finding indicates that the IgM present at birth and germ line polyreactive IgM was adsorbed by the xenografts. The depletion of polyreactive antibodies (43-83% reduction of anti-DNP IgM) from adult baboons was also observed following pulmonary xenotransplantation or immunoadsorption therapy plus pulmonary xenotransplantation. Additional experiments using human cord serum indicated that most human polyreactive IgM were adsorbed by pig lung homogenate and that the human polyreactive IgM bound approximately two-fold more to immobilized pig lung antigens than to immobilized human lung antigens. These findings indicate that germline polyreactive antibodies are, for the most part, xenoreactive. These data suggest that polyreactive antibodies, although autoreactive, may be more xenoreactive than autoreactive.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680568     DOI: 10.1016/s0966-3274(01)00047-8

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

Review 1.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 2.  Is There a Role for Natural Antibodies in Rejection Following Transplantation?

Authors:  Emmanuel Zorn; Sarah B See
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

Review 3.  Polyreactive natural antibodies in transplantation.

Authors:  Emmanuel Zorn; Sarah B See
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.